ReviewJournal of the American Society of Nephrology : JASN2025
Antineutrophil Cytoplasmic Antibodies (ANCAs): Role in Diagnosis, Disease Monitoring, and Prognosis.
Review in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-World Concordance of Indirect Immunofluorescence and Antigen-Specific Assays in Antineutrophil Cytoplasmic Antibody Testing: A Retrospective High-Volume Laboratory Study.The Eurasian journal of medicine · 2026Article
- Article
- Urinary complement C3 fragment levels and their clinical relevance in MPO-ANCA-associated vasculitis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ANCA-associated vasculitis (AAV) is a rare and potentially fatal autoimmune disorder characterized by pauci-immune necrotizing vasculitis affecting small- to medium-sized blood vessels. The pathogenic role of ANCAs in AAV is supported by both clinical and experimental evidence, and when used in the proper clinical setting, ANCA testing is highly specific for AAV. Testing with both indirect immunofluorescence assay and enzyme immunoassay may increase sensitivity for AAV; however, testing with a high-quality enzyme immunoassay may be used alone. Nonvasculitic conditions and drugs can cause ANCA positivity without manifestations of AAV. We review ANCA testing itself, performance characteristics and specific conditions for the laboratory test, and various conditions when ANCA testing is useful in diagnosis, disease monitoring, and selecting treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.